Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Formiminotransferase cyclodeaminase N-terminal like (FTCDNL1) is a protein-coding gene in humans with strong sequence similarity to the N-terminal domain of formiminotransferase-cyclodeaminase enzymes, but its specific biological function in humans is not well defined[4][7]. It is predicted to enable folic acid binding and transferase activity and belongs to the SPATS2 protein family[3][4]. FTCDNL1 is distinct from FTCD (formimidoyltransferase-cyclodeaminase), which is an established metabolic enzyme involved in amino acid and folate metabolism[1][2]. While FTCDNL1 is annotated in public databases and has several sequence aliases, it is not a well-characterized enzyme, receptor, transporter, or canonical therapeutic target in current biomedical literature and does not yet have an established role in human disease or pharmacology[3][4][9].
Not established; no drugs with characterized mechanism against this molecule
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Formiminotransferase cyclodeaminase N-terminal like (FTCDNL1).